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Background: Esophagogastric junctional (EGJ) cancer occurs in the mucosa near the esophagogastric junction, and
has characteristics of both esophageal and gastric malignancies; its optimal treatment strategy is controversial.
Methods: We conducted a single-center retrospective cohort study of the patients who underwent curative
surgery with lymphadenectomy for EGJ cancer. Tumor specimens were categorized by histology and location into
four types—centered in the esophagus < 5 cm from EGJ (type E), which were subtyped as (i) squamous-cell
carcinoma (SQ) or (ii) adenocarcinoma (AD); (iii) any histological tumor centered in the stomach < 5 cm from EGJ,
with EGJ invasion (type Ge); (iv) any histological tumor centered in the stomach < 5 cm from EGJ, without EGJ
invasion (type G)—and classified by TNM system; these were compared to patients’ clinicopathological
characteristics and survival outcomes.
Results: A total of 92 EGJ cancer patients were studied. Median follow-up of surviving patients was 35.5 months.
Tumors were categorized as 12 type E (SQ), 6 type E (AD), 27 type Ge and 47 type G; of these 7 (58.3%), 3 (50%), 19
(70.4%) and 14 (29.8%) and 23 patients, respectively, had lymph node metastases. No patients with type E (AD) and
Ge tumors had cervical lymph node metastasis; those with type G tumors had no nodal metastasis at cervical and
mediastinal lymph nodes. Multivariate analysis showed that type E (AD) tumor was an independent prognostic
factor.
Conclusions: We should distinguish type Ge tumor from type E (AD) tumor because of the clinicopathological and
prognostic differentiation. Extended gastrectomy with or without lower esophagectomy according to tumor
location and lower mediastinal and abdominal lymphadenectomy are recommended for EGJ cancer.
Trial registration: University Hospital Medical Information Network in Japan, UMIN000008596.
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Gastric and esophageal cancers are, respectively, the
fourth and eighth most common cancers in the world,
and the second and sixth most common causes of
cancer-related death, affecting approximately 736,000
and 406,000 people in 2008 [1]. Esophagogastric junc-
tional cancer (EGJC), which is increasing in Western
countries, is a tumor occurring at the mucosa between the
lower esophagus and cardia, and has clinicopathological* Correspondence: h.ito@med.showa-u.ac.jp
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reproduction in any medium, provided the orcharacteristics of both esophageal and gastric malignan-
cies [2,3].
Siewert classification is widely used to categorize EGJ
adenocarcinoma [4,5]. Siewert defines adenocarcinoma
of the distal esophagus, such as that from specialized
esophageal metaplasia (e.g., Barrett’s esophagus) as type
I; cardiac carcinoma, from the cardia epithelium or
within 1 cm (along the esophagus) or 2 cm (in the stom-
ach) from the EGJ as type II; and subcardial gastric car-
cinoma with epicenter in the proximal 5 cm of the
stomach, which infiltrates the EGJ and distal esophagus,
as type III. Because the Siewert type I tumor is locatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Tumor classification. We categorized tumors near the EGJ into four types according to its location and main histological type.
Categorization criteria were: (i) squamous-cell carcinoma with epicenter in the esophagus within 5 cm from EGJ (type E (SQ)); (ii)
adenocarcinoma with epicenter in the esophagus within 5 cm from EGJ (type E (AD)); (iii) any histological tumor with epicenter in the stomach
within 5 cm from EGJ, with EGJ invasion (type Ge); (iv) any histological tumor with epicenter in the stomach within 5 cm from EGJ, without EGJ
invasion (type G). Type E (SQ), E (AD) and Ge tumors were categorized as esophageal cancer; type G tumor was categorized as gastric cancer by
the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) Cancer Staging Manual. Siewert type I and III tumors
were categorized as type E (AD) and Ge tumors, and Siewert type II tumor was categorized as type E (AD) or Ge tumor in this study.
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esophageal cancer; whereas type III tumor has similar
clinicopathological characteristics to cardiac cancer be-
cause of its location. However, Siewert type II tumor is a
metastatic threat to both thoracic and abdominal areas,
as it crosses the EGJ. Subtotal esophagectomy offers only
a limited benefit and should not be performed for type
II cancer. The TNM staging system according to the sev-
enth edition of the American Joint Committee on Can-
cer/International Union Against Cancer (AJCC/UICC)
Cancer Staging Manual defined EGJC, including ofFigure 2 Flow diagram of the patients in this study. Total 92 patients w
junctional cancer at the Digestive Disease Center, Showa University Northe
were retrospectively studied.squamous-cell carcinoma and adenocarcinoma centered
in the esophagus within 5 cm, and in the proximal 5 cm
of the stomach with crossing the EGJ [6,7]. AJCC/UICC
also categorizes any cardiac cancer without EGJ invasion
as gastric cancer regardless of its location. Different sta-
ging systems are applied to esophageal squamous-cell
carcinoma and esophageal adenocarcinoma.
Surgery is effective treatment for resectable esophageal
[8,9] and gastric cancer [10-12]. However, as esophagect-
omy is generally more invasive than gastrectomy [13], we
should be careful in treating EGJC with esophagectomy.ho underwent curative surgical resection for esophagogastric
rn Yokohama Hospital between October 2001 and December 2010
Table 1 Patient characteristics (n = 92)
Variables
Age (year, mean ± SD) 65.9 ± 9.4
Sex Male 72 (78.3%)
Female 20 (21.7%)
Siewert classification Type I adenocarcinoma 2 (2.2%)
Type II adenocarcinoma 16 (17.4%)
Type III adenocarcinoma 11 (12.0%)
Not applicable 63 (68.5%)
Macro type Type 0 36 (39.1%)
Type 1 4 (4.3%)
Type 2 26 (28.3%)
Type 3 21 (22.8%)
Type 4 1 (1.1%)
Type 5 4 (4.3%)
Preoperative chemotherapy No 79 (85.9%)
Yes 13 (14.1%)
Extent of surgical resection Subtotal esophagectomy with partial gastrectomy 14 (15.2%)
Proximal gastrectomy with partial esophagectomy 30 (32.6%)
Total gastrectomy with partial esophagectomy 48 (52.2%)
Extent of lymph node dissection Abdominal, mediastinal and cervical 11 (12.0%)
Abdominal and mediastinal 9 (9.8%)
Abdominal and lower mediastinal† 27 (29.3%)
Abdominal 45 (48.9%)
Pathological tumor size (mm, mean ± SD) 46.1 ± 23.7
Main histologic type Adenocarcinoma 79 (85.9%)
Squamous-cell carcinoma 13 (14.1%)
Lymphatic invasion L0 32 (34.8%)
L1 60 (65.2%)
Venous invasion V0 32 (34.8%)
V1–2 60 (65.2%)








Distant metastasis pM0 72 (78.3%)
pM1 20 (21.7%)
TNM stage pStage I 36 (39.1%)
pStage II 19 (20.7%)
pStage III 17 (18.5%)
pStage IV 20 (21.7%)
Ito et al. Journal of Experimental & Clinical Cancer Research 2013, 32:2 Page 3 of 12
http://www.jeccr.com/content/32/1/2
Table 1 Patient characteristics (n = 92) (Continued)
Adjuvant chemotherapy No 43 (46.7%)
Yes 49 (53.3%)
† Including lower thoracic paraesophageal, diaphragmatic and posterior mediastinal lymph node.
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with EGJC to investigate its optimal management.
Methods
Study design
We performed a single center, retrospective cohort study.
We studied patients who underwent curative surgery for
EGJC, including lymph node dissection, at the Digestive
Disease Center, Showa University Northern Yokohama
Hospital, between October 2001 and December 2010.
Clinicopathological data and prognosis were taken from
medical records.
Patients
We studied patients with cancer in the lower esophagus
and cardia. Inclusion criteria were: (i) presence of histolo-
gically proven carcinoma centered within the lower 5 cm
of the esophagus and the upper 5 cm of the stomach; (ii)
clinically solitary tumors; (iii) no prior endoscopic resec-
tion or surgical treatment; and (iv) patient aged 20–
80 years. The exclusion criteria were: (i) presence of severe
organ dysfunction; (ii) presence of metachronous and syn-
chronous malignancy; and (iii) presence of pathological
non-curative findings.
All patient data were approved for use by the institu-
tional review board of Showa University Northern
Yokohama Hospital. This study was registered with the
University Hospital Medical Information Network in
Japan (No. UMIN000008596).
Classification
Although Siewert classification is one of the most widely
used criteria for EGJC, it is generally used for only
adenocarcinoma. EGJC, including squamous cell carcin-
oma, has been defined by the seventh edition of AJCC/
UICC TNM Cancer Staging Manual. However, it does
not cover all of the cancer near the EGJ—for example a
localized gastric adenocarcinoma with centered in the
stomach within 5 cm from EGJ. Thus, we categorized
tumors near the EGJ into four types, according to loca-
tion and main histological type (Figure 1). Categorization
criteria were: (i) squamous-cell carcinoma centered in
the esophagus within 5 cm from EGJ (type E (SQ)); (ii)
adenocarcinoma centered in the esophagus within 5 cm
from EGJ (type E (AD)); (iii) any histological tumor cen-
tered in the stomach within 5 cm from EGJ, with EGJ in-
vasion (type Ge); (iv) any histological tumor centered in
the stomach within 5 cm from EGJ, without EGJ invasion(type G). All disease was pathologically staged using the
seventh edition of AJCC/UICC TNM Cancer Staging
Manual [6,7]. Thus, types E and Ge tumors were staged
as esophageal cancer, and type G tumor was staged as
gastric cancer.
Statistical analysis
Statistical analysis was performed using JMP 9.0.3 (SAS
Institute, Cary, USA). We used Fisher’s exact test and
Pearson’s chi-squared test to compare the characteristics
of the patients and pathological findings. The nonpara-
metric Kruskal–Wallis test was used to assess differences
among patients’ age groups, number of dissected lymph
nodes and pathological tumor size. Kaplan–Meier curves
of estimated overall survival were generated and com-
pared, using a 2-sided log-rank test. To investigate prog-
nostic factors, Cox proportional hazard analysis was
used. Multivariate analysis included tumor types and
variables with P < 0.10 in univariate analysis. P < 0.05
was considered statistically significant.
Results
Patient characteristics
A total of 92 patients were included in this study
(Figure 2). Median follow-up of surviving patients was
35.5 months. Patients’ characteristics are summarized in
Table 1. Approximately 80% of them were men; their
average age was 65.9 years (range: 35–80 years). Four-
teen (15.2%), 30 (32.6%) and 48 (52.2%) patients under-
went subtotal esophagectomy with partial gastrectomy,
proximal gastrectomy with partial esophagectomy and
total gastrectomy with partial esophagectomy, respect-
ively. Twenty-four patients underwent splenectomy to
remove involved lymph nodes at the splenic hilum. Thir-
teen patients (14.1%) received preoperative chemother-
apy. Histologically, 79 (85.9%) and 13 (14.1%) of 92
patients had tumors mainly composed with adenocarcin-
oma and squamous cell carcinoma. Mean pathological
tumor size was 46.1 mm. Two, 16 and 11 tumors were
categorized as Siewert types I, II and III, respectively;
Siewert classification was not applicable to the
remaining 63 tumors. In 63 tumors which did not apply
to Siewert classification, 50 and 13 tumors were mainly
composed with adenocarcinoma and squamous cell car-
cinoma. However 15 and 48 tumors centered in the
esophagus and the stomach, only one tumor had esopha-
gogastric junctional invasion. Eighteen (19.6%), 27
(29.3%) and 47 (51.1%) tumors were categorized type E,
G and Ge, respectively. The mean number of dissected
Table 2 Comparison of clinicopathological characteristics
Variable Type E (SQ) (n = 12) Type E (AD) (n = 6) Type Ge (n = 27) Type G (n = 47) P-value
Sex 0.906
Male 10 5 20 37
Female 2 1 7 10
Age (mean ± SD) 64.4 ± 6.84 66.3 ± 7.97 65.2 ± 10.6 66.5 ± 9.67 0.728
Extent of surgical resection < 0.001**
Subtotal esophagectomy with partial gastrectomy 11 3 0 0
Proximal gastrectomy with partial esophagectomy 1 1 8 20
Total gastrectomy with partial esophagectomy 0 2 19 27
Extent of lymph node dissection < 0.001**
Abdominal, mediastinal and cervical 9 2 0 0
Abdominal and mediastinal 2 3 4 0
Abdominal and lower mediastinal† 1 1 17 8
Abdominal 0 0 6 39
Number of dissected lymph nodes (mean ± SD) 28.1 ± 12.1 28.7 ± 18.1 46.4 ± 34.6 35.3 ± 26.8 0.295
Pathological tumor size (mm, mean ± SD) 46.3 ± 22.4 41.5 ± 36.4 62.2 ± 18.6 37.9 ± 20.5 < 0.001**
Main histological type < 0.001**
Squamous cell carcinoma 12 0 1 0
Adenocarcinoma 0 6 26 47
Esophagogastric junctional invasion < 0.001**
Yes 6 3 27 0
No 6 3 0 47
Siewert classification < 0.001**
Type I 2 0 0 0
Type II 1 0 15 0
Type III 0 0 11 0
Not applicable 3 12 1 47
Depth of tumor invasion 0.025*
pT1 3 3 4 23
pT2 0 1 3 7
pT3 9 2 14 10
pT4 0 0 6 7
Lymph node metastasis 0.005**
pN0 3 3 8 33
pN1 6 2 6 5
pN2 2 1 5 6
pN3 1 0 8 3
Distant metastasis < 0.001**
M0 8 5 12 47
M1 4 1 15 0
TNM Stage < 0.001**
pStage I 2 3 4 27
pStage II 2 0 6 11
pStage III 4 2 2 9
pStage IV 4 1 15 0
* P < 0.05, ** P < 0.01.
† Including lower thoracic paraesophageal, diaphragmatic and posterior mediastinal lymph node.
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Table 3 Number of patients with positive nodes
Variable Type E (SQ) (n = 12) Type E (AD) (n = 6) Type Ge (n = 27) Type G (n = 47) P-value
Overall 7/12 (58.3%) 3/6 (50.0%) 19/27 (70.4%) 14/47 (29.8%) 0.003**
Depth of tumor invasion
pT1 2/3 (66.7%) 0/3 2/4 (50.0%) 0/23 0.001**
pT2 – 1/1 (100%) 2/3 (66.7%) 3/7 (42.9%) 0.497
pT3 5/9 (55.6%) 2/2 (100.0%) 9/14 (64.3%) 6/10 (60.0%) 0.697
pT4 – – 6/6 (100%) 5/7 (71.4%) 0.269
Main histological type
Squamous-cell carcinoma 7/12 (66.7%) – 0/1 – 0.462
Adenocarcinoma – 3/6 (50.0%) 19/26 (73.1%) 14/47 (29.8%) 0.002**
Location of lymph node†
Cervical LN 2/9 (22.2%) 0/2 – – 0.655
Upper–middle mediastinal 0/11 0/5 0/4 – –
Lower mediastinal‡ 2/12 (16.7%) 2/6 (33.3%) 2/20 (10.0%) 0/8 0.298
Perigastric LN 6/12 (50.0%) 3/6 (50.0%) 17/27 (63.0%) 13/47 (27.7%) 0.026*
Left paracardial 1 2 8 2
Right paracardial 3 3 10 5
Lesser curvature 4 1 13 10
Greater curvature 0 1 4 1
Suprapyloric 0 0 0 0
Infrapyloric 0 0 1 0
LN along left gastric artery 2/12 (16.7%) 1/6 (16.7%) 5/27 (18.5%) 7/47 (14.9%) 0.983
LN at Celiac trunk 0/6 0/3 1/19 (5.3%) 2/24 (8.3%) 0.837
LN along hepatic artery 0/3 0/1 3/19 (15.8%) 1/27 (3.7%) 0.459
LN along splenic artery 0/2 1/3 (33.3%) 2/22 (9.1%) 1/23 (4.3%) 0.356
LN at splenic hilum – – 3/17 (17.6%) 0/9 0.262
* P < 0.05; ** P < 0.01.
† Number of the patients with nodal metastasis/number of the patients underwet lymph node dissection (%).
‡ Lower thoracic paraesophageal, diaphragmatic and posterior mediastinal lymph node.
LN Lymph node.
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five (48.9%) of 92 patients had lymph node metastases
(pN1–3). Thirty-six (39.1%), 19 (20.7%), 17 (18.5%) and
20 (21.7%) patients were pathologically staged I, II, III
and IV, respectively. Forty-nine patients (53.3%) had pre-
operative chemotherapy.
Comparison of clinicopathological characteristics among
type E (SQ), E (AD), Ge and G tumor group are summar-
ized in Table 2. There were significant differences in extent
of surgical resection, pathological tumor size, main histo-
logical type, depth of tumor invasion (pT category), lymph
node metastasis (pN category), distant metastasis (pM cat-
egory) and TNM tumor stage. Histologically, 26 (96.3%) of
27 type Ge tumor and all 47 type G tumors were adenocar-
cinoma. Patients with Type G tumors tended to have earl-
ier stage diseases than the other tumor groups.
Incidence of lymph node metastases were summarized
in Table 3. Seven (58.3%) of 12 type E (SQ) tumors, 3
(50.0%) of 6 type E (AD) tumors, 19 (70.4%) of 27 typeGe tumors and 14 (29.8%) of 47 type G tumors had
lymph nodes metastases (P = 0.003). Although incidence
of nodal metastasis in pT1 tumor was significantly lower
in the type G tumor group than the other type tumor
groups, there was no significant difference in pT2, pT3
and pT4 tumors among 4 tumor groups. With regard to
lymph node location, no nodal metastasis in the cervical
and mediastinal lymph nodes was seen in the type G
tumor group. Although nodal metastases in perigastric
lymph nodes were seen in all tumor types, only one nodal
metastasis in intra-abdominal lymph nodes, except for
perigastric lymph nodes, was recognized in type E tumor
group. Nodal metastasis at the splenic hilum was seen in
only in the Ge tumor group. As a result, incidence rates
for nodal metastasis in cervical, mediastinal, and perigas-
tric lymph nodes differed among 4 patients groups.
Clinicopathological characteristics and clinical courses
of seven patients with cervical or mediastinal lymph
node metastasis were summarized in Table 4. The















pT pN pM Stage Initial recurrence
site
Status
1 E (SQ) SC – 64 M 50 65 Type 0 SQ (por) T3 N3 M0 IIIC LN, lt. adrenal grand Deceased
2 E (SQ) SC LTP 57 M 87 69 Type 0 SQ (por) T1 N2 M1 IV LN Deceased
3 E (SQ) – EH 72 M 25 40 Type 2 SQ (mod) T3 N1 M0 IIIA LN Deceased
4 E (AD) – EH 73 F 110 100 Type 0 AD (por) T2 N1 M0 IIB Peritoneum Deceased
5 E (AD) – LTP, ID 62 M 45 55 Type 2 AD (mod) T3 N1 M0 IIIA LN Deceased
6 Ge – LTP 68 M 80 30 Type 1 AD (mod) T3 N3 M0 IIIC Deceased (other
cause)
7 Ge – EH 41 M 65 25 Type 3 AD (por) T3 N3 M1 IV LN Alive with relapse
† Distance between proximal edge of tumor and EGJ in mm.



















Figure 3 Overall survival of patients. (A) Patients with pT1–4 tumors (n = 92). Type G tumor group demonstrated higher overall survival rate
compared with type E adenocarcinoma (AD) (P = 0.013) tumor group. Although not significantly, the type G tumor group had a higher survival
rate than the type E squamous-cell carcinoma (SQ) (P = 0.366) and Ge (P = 0.850) tumor group. (B) Patients with pT2–4 Tumors (n = 59). The type
E (AD) tumor group demonstrated significantly lower overall survival rate compared with the type Ge (P = 0.001) and type G (P = 0.003) tumor
group. The type E (AD) tumor group had a lower survival rate than the type E (SQ) tumor group (P = 0.076) although not significantly.
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the lower mediastinal area. Six of 7 patients had disease
recurrence and 5 patients were deceased. One patient
died of another cause without disease recurrence.
Surgical outcomes
The 5-year overall survival rate was 56.6%. Thirty-three
patients had disease recurrence. Thirty-four patients
deceased. Twenty-five, 1 and 8 patients died of cancer,
surgical complication and other causes. Overall survival
rates were compared among the patients with type E
(SQ), E (AD), G and Ge tumors. In patients with pT1–4
tumors, the type G tumor group (overall 5-year survival
rate was 64.4%) demonstrated higher overall survival
rate compared with type E (AD) (overall 5-year survival
rate was 33.3%) (P = 0.013) tumor group. Although not
significantly, the type G tumor group had a higher sur-
vival rate than the type E (SQ) (overall 5-year survival
rate was 50.0%) (P = 0.366) and Ge (overall 5-year sur-
vival rate was 51.9%) (P = 0.850) tumor group(Figure 3A). Because the type G tumor group had rela-
tively early-stage disease, survival rates were calculated
in patients with pT2–4 tumor. In the pT2–4 group, the
type E (AD) tumor group demonstrated significantly
lower overall survival rate compared with the type Ge
(overall 5-year survival rate was 49.4%) (P = 0.001) and
type G (overall 5-year survival rate was 42.8%)
(P = 0.003) tumor group. The type E (AD) tumor group
had a lower survival rate than the type E (SQ) tumor
group (overall 5-year survival rate was 44.4%) (P = 0.076)
although not significantly (Figure 3B).
Prognostic factor
A univariate Cox proportional hazard analysis showed
that lymphatic invasion (P < 0.001) and venous invasion
(P < 0.001), depth of tumor invasion (pT category;
P < 0.001), lymph node metastasis (pN category;
P < 0.001), distant metastasis (M category; P = 0.028)
were statistically significant for survival. Sex, age and
Table 5 Univariate Cox proportional hazards analysis of overall survival
Variable Hazard ratio 95% confidence interval P-value
Sex
Male (n = 72) 1.0
Female (n = 20) 1.391 0.611 – 2.898 0.412
Age (years)
≤ 65 (n = 38) 1.0
> 65 (n = 54) 1.141 0.573 – 2.351 0.711
Main histological type
Squamous-cell carcinoma (n = 13) 1.0
Adenocarcinoma (n = 79) 0.707 0.323 – 1.769 0.432
Lymphatic invasion
L0 (n = 32) 1.0
L1 (n = 60) 7.221 2.558 – 30.22 < 0.001**
Venous invasion
V0 (n = 32) 1.0
V1–2 (n = 60) 4.772 1.872 – 16.12 < 0.001**
Depth of tumor invasion
pT1–2 (n = 44) 1.0
pT3–4 (n = 48) 4.521 1.993 – 12.14 < 0.001**
Lymph node metastasis
pN0 (n = 47) 1.0
pN1–3 (n = 45) 4.597 2.096 – 11.54 < 0.001**
Distant metastasis
M0 (n = 72) 1.0
M1 (n = 20) 2.257 1.094 – 4.496 0.028*
* P < 0.05; ** P < 0.01.
LN Lymph node.
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with survival (Table 5). A multivariate Cox proportional
hazard analysis that included variables with P < 0.10 in
univariate analysis and tumor type (types E (SQ), E
(AD), Ge and G) showed that tumor type was an inde-
pendent significant prognostic factor (Table 6). Among
tumor types, the type E (AD) tumor group demon-
strated significantly higher risk in survival than did the
type E (SQ) (hazard ratio: 0.224; 95% confidence inter-
val, 0.062–0.911; P = 0.038), Ge (hazard ratio: 0.162;
95% confidence interval, 0.048–0.643; P = 0.012) and G
(hazard ratio: 0.219; 95% confidence interval, 0.069–
0.839; P = 0.029) tumor group. In the depth of tumor in-
vasion, pT1–2 tumor demonstrated significantly lower
survival risk than did pT3–4 (hazard ratio: 2.937; 95%
confidence interval, 1.168–8.698; P = 0.021) tumor.
Regarding lymphatic invasion, L1 showed higher sur-
vival risk, however there was no significance (hazard
ratio: 4.575; 95% confidence interval, 0.940–25.80; P =
0.060). Venous invasion, lymph node metastasis (pN
category) and distant metastasis (M category) were not
significant predictors of survival.Discussion
The aim of this study was to clarify the clinicopathologi-
cal characteristics of cancers around the EGJ, and to in-
vestigate optimal management. Standard treatment for
EGJC is controversial for several reasons. One of them is
that the definition of EGJC is not stable. Siewert et al.
define EGJC as adenocarcinoma, centered in area be-
tween the lowest 5 cm of the esophagus and the upper
5 cm of the stomach, and crossing the EGJ [14]. The
Japanese Classification of Esophageal Cancer (JCEC)
from the Japan Esophageal Society defines EGJC as
being within the lower 2 cm of the esophagus and the
upper 2 cm of the stomach, because of histological evi-
dence of spreading of columnar epithelium-lined lower
esophagus [15]. Moreover, AJCC defines EGJ as includ-
ing squamous-cell carcinoma in the same locations as
with Siewert classification [4].
However Siewert classification is widely used, its appli-
cation is limited for adenocarcinoma. Although EGJC, as
defined by the AJCC cancer staging manual, includes
squamous-cell carcinoma, it does not categorize any
tumor without EGJ invasion as EGJC—as does Siewert
Table 6 Multivariate Cox proportional hazards analysis of overall survival
Variable Hazard ratio 95% confidence interval P-value
Tumor type
Type E (AD) (n = 6) 1.0
Type E (SQ) (n = 12) 0.224 0.062 – 0.911 0.038*
Type Ge (n = 27) 0.162 0.048 – 0.643 0.012*
Type G (n = 47) 0.219 0.069 – 0.839 0.029*
Lymphatic invasion
L0 (n = 32) 1.0
L1 (n = 60) 4.575 0.940 – 25.80 0.060
Venous invasion
V0 (n = 32) 1.0
V1–2 (n = 60) 0.966 0.196 – 5.170 0.967
Depth of tumor invasion
pT1–2 (n = 44) 1.0
pT3–4 (n = 48) 2.937 1.168 – 8.698 0.021*
Lymph node metastasis
pN0 (n = 47) 1.0
pN1–3 (n = 45) 1.460 0.463 – 5.607 0.537
Distant metastasis
M0 (n = 72) 1.0
M1 (n = 20) 1.097 0.428 – 2.794 0.846
* P < 0.05.
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different staging systems for squamous-cell carcinoma
and adenocarcinoma, this method may be too complex
for clinicians; whereas the JCEC system, which treats
most limited tumors as EGJC, is more precise.
Because of the unstable definition of EGJCs, clinico-
pathological characters and treatment strategies have not
been unified. Siewert et al. argued that complete surgical
resection and lymph node metastasis were independent
prognostic factors in type II adenocarcinoma, and subtotal
esophagectomy had less survival effectiveness for the
patients with type II adenocarcinoma [5]. Hasegawa et al.
reported that about 40%, 60% and 90% of patients with
type I, II and III tumors, respectively, had lymph node me-
tastases, and recommended complete resection for im-
proving survival [16]. Schiesser et al. reported that
subtotal esophagectomy and extended total gastrectomy
should be performed for type I and type II–III tumor [17].
With regard to surgical approach, Sasako et al. showed
that the left thoracoabdominal approach did not improve
survival after the abdominal-transhiatal approach and
leads to increased morbidity in patients with cancer of the
cardia or subcardia [18]. Kakeji et al. reported that esopha-
gectomy with mediastinal and abdominal lymphadenect-
omy was adequate for squamous-cell carcinoma, and
that extended total gastrectomy with lower mediastinal
and abdominal lymphadenectomy was suitable foradenocarcinoma [19]. Carboni et al. maintained effects of
extended gastrectomy by an abdominal–trans-hiatal ap-
proach for EGJC [20]. Conversely, Chau et al. reported
that performance status, liver metastasis, peritoneal me-
tastasis and alkaline phosphatase were independent prog-
nostic factors in patients with locally advanced and
metastatic EGJC, and that prognoses of patients with re-
current disease were no better than those without surgery
[21].
We studied any tumor centered in area between the
lowest 5 cm of the esophagus and the upper 5 cm of the
stomach, regardless of histological type and EGJ inva-
sion, and simply categorized them in 4 groups including
type E (SQ), E (AD), Ge and G.
Whereas type E (SQ), E (AD) and Ge tumors in this
study are categorized as esophageal cancer by AJCC/
UICC criteria, these tumor groups show differences in
clinicopathological characteristics. In lymph node metas-
tasis, approximately 60%, 50%, 70% and 30% of the
patients with type E (SQ), E (AD), Ge and G tumors re-
spectively had lymph node metastases in this study. Cer-
vical lymph node metastases were recognized in only
type E (SQ) tumor group. Because type E (AD) tumor
was based on columnar epithelium, its histological be-
havior was thought to be similar to cardiac adenocarcin-
oma; however, type E (AD) tumor showed a nodal
metastatic spreading pattern similar to that of type Ge
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unite type E (AD) and Ge tumors as a group on the
basis of lymphadenectomy extent, the patients with type
E (AD) tumor showed significantly lower survival rates
than other type tumor groups. Although not signifi-
cantly, patients with type E (AD) tumor had higher inci-
dence of nodal metastasis at mediastinal lymph node
than did patients in tumor groups, and all mediastinal
positive nodes existed in lower mediastinal area. Thus,
subtotal esophagectomy is not necessary for type E (AD)
and Ge tumor, if complete tumor resection can be
achieved. Because no cervical or mediastinal lymph node
metastasis was recognized in the type G tumor group,
we should not perform subtotal esophagectomy for type
G tumor. In multivariate analysys, tumor type (type E
(AD)) was an independent risk factor for survival of the
patients with EGJC in this study. The prognosis of cer-
vical or mediastinal node positive patients was poor. Be-
cause survival benefit by cervical and mediastinal
lymphadenectomy for the node positive patients with
EGJC is limited, we should carefully perform subtotal
esophagectomy, and cervical and mediastinal lymphade-
nectomy for EGJC patients. Therefore, extended gastrec-
tomy with or without lower esophagectomy, according
to tumor location, and lower mediastinal and abdominal
lymphadenectomy is thought to be adequate for patients
with EGJC, including type E (SQ) tumor.
Although lymphatic invasion, venous invasion, depth
of tumor invasion (T category), lymph node metastasis
(N category) and distant metastasis (M category) were
significantly prognostic factors in the univariate analysis,
tumor type (types E (SQ), E (AD), Ge and G) and depth
of tumor invasion (pT3–4 tumor) were significant in the
multivariate analysis in this study. It was reported that
complete surgical resection and lymph node metastasis
were independent prognostic factors in type II adenocar-
cinoma [5]. We believe that the lack of a significant dif-
ference between the prognosis and lymph node
metastasis can be explained by limitations of this study
such as the small sample size. Distant metastasis (M cat-
egory) was not significantly prognostic factor in the
multivariate analysis in study. AJCC/UICC TNM staging
system for esophageal cancer defines nodal metastasis
along lesser curvature as distant metastasis, although
lymph node along lesser curvature is one of the main re-
gional lymph nodes of gastric cancer. Because majority
of the patient with M1 disease had no hematogenous
metastasis in this study, there was a possibility that dis-
tant metastasis was not significant for prognosis in this
study.
Reim et al. reported that chemotherapy to be more ef-
ficacious for EGJC than for distal gastric cancer [22].
The treatment efficacy of chemotherapy before or after
surgery is unclear in this small scale retrospective cohortstudy. To clarify optimal treatment strategy for EGJC,
we should confirm the results in this study using a large
scale prospective study.
Conclusions
Patients with type E (AD) and Ge tumor had no cervical
lymph node metastasis, and those with type G tumor
had no nodal metastasis at cervical and mediastinal
lymph node. The incidence of mediastinal lymph node
metastasis of type E (AD) tumor group was higher than
type Ge tumor group, and survival rate of the patients
with type Ge tumor is significantly higher than those
with type E (AD) tumor. Therefore we should distin-
guish type Ge tumor from type E (AD) tumor. Based on
our findings from a retrospective analysis in this cohort
study, we suggest performing extended gastrectomy with
or without lower esophagectomy, according to tumor lo-
cation, and lower mediastinal and abdominal lymphade-
nectomy for EGJC.
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